Please assess the completion status of the following clinical trial:

Trial Title: Short-term Effects of Perindopril-amlodipine Versus Perindopril-indapamide in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* adult diabetes patients aged between 25-65 years,~* with grade I or grade II (WHO classification) hypertension on the clinical measure, confirmed by ABPM~* naïve to any anti-hypertensive treatment~* written informed consent.~Exclusion Criteria:~* Patients with grade III hypertension (WHO classification) were classified as hypertensive emergency,~* estimated creatinine clearance ˂30ml/min/1.73m2 (using Modified Diet in Renal Diseases formula)~* alanine transaminase (ALT)≥ 3 normal~* any contraindication to study drugs (hypersensitivity)~* pregnant or breastfeeding women

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Perindopril and Amlodipine (Type: EXPERIMENTAL): Fixed dose combination of Perindopril 5mg and Amlodipine 5mg tablets once daily for 6 weeks
- Perindopril-Indapamide (Type: ACTIVE_COMPARATOR): Fixed-dose combination of Perindopril 5mg and Indapamide 1.25mg tablets once daily for 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).